CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®) Results include a 9.3% weight reduction ...

Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option.1 ...

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...

Chairman, six board members to stand down next month Top shareholder proposes new board members Former Novo CEO Sorensen to become chair for 2-3 years Boardroom feud comes in midst of company ...

Novo Nordisk Chairman Helge Lund, along with several other board members, will be leaving their positions following a disagreement with the company's largest shareholder, the Novo Nordisk Foundation.

Novo Nordisk A/S Chairman Helge Lund is stepping down after a boardroom dispute over the pace of change and will be replaced by Lars Rebien Sorensen, a previous leader of the Danish drugmaker who now ...

There's still no oral GLP-1 pill dedicated to treating obesity, however, Novo Nordisk has filed a separate case to the FDA seeking approval for its once-daily oral semaglutide (Wegovy). This decision ...

Novo Nordisk shares slumped Friday after President Trump said he would lower the price of the Danish company’s Ozempic drug for Americans. Speaking in the Oval Office Thursday, Trump said the cost of ...

Novo Nordisk NOVO.B-2.39%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on ...

The Novo Nordisk Foundation has committed up to 200 million Danish kroner ($31 million) to support a new, artificial-intelligence-enabled system to monitor infectious disease outbreaks and bolster ...